Former Cincinnati Bearcats great Nick Van Exel is under the impression UC's next head coach will be Utah State's Jerrod Calhoun, and Van Exel seems to be just fine with that. "Calhoun is going to be ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Exelixis (EXEL) is back in focus after reporting earnings ...

Sedrani previously led Exel’s establishment as a Merak Capital subsidiary and scaled its accelerator operations. He also serves as VP of innovation platform at Merak Capital, overseeing growth-focused ...

Nick Van Exel didn't choose Cincinnati because it was prestigious. He chose it because Louisville, UNLV and Syracuse said no to him. What he didn't realize was that the rejection mattered less than ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value ...

Shares of Exelixis (EXEL) slipped on Monday after Bank of America downgraded the cancer drugmaker to Underperform from Neutral and lowered its target price to $41 from $43, citing concerns over its ...

Exel has entered into a new purchasing agreement with global resin specialist Polynt to purchase hundreds of tonnes of its bio-based unsaturated polyester resin (UPR). The collaboration represents ...

Each startup receives $300,000, increasing the total investment due to the larger group. Selected studios gain mentorship and hands-on support from global industry leaders. Applications for Cohort 3 ...

Players selected in the second round rarely, if at all, get to show off their skills in the NBA. However, Nick Van Exel was one of the few who got to ball out and even reach All-Star status. A 6'1" ...

Exelixis, Inc. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. On September 17, Barclays began coverage of Exelixis, Inc. (NASDAQ:EXEL), rating it Equalweight and setting a ...

Goldman Sachs launched its coverage of Exelixis (NASDAQ:EXEL) with a Buy recommendation and a $47 target, citing the potential of its lead candidate, zanzalintinib, in offsetting an upcoming patent ...